Skip to content

Estimation of Benefit From Regular Versus Leakage-related Exchange of Voice Prosthesis in Patients Post Laryngectomy.

Estimation of Benefit From Regular Versus Leakage-related Exchange of Voice Prosthesis in Patients Post Laryngectomy Considering Complications Rate, Fistula Colonization by Candida Species and Patients Satisfaction Feedback.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04268459
Acronym
RvLPE
Enrollment
70
Registered
2020-02-13
Start date
2020-03-10
Completion date
2022-03-31
Last updated
2020-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laryngectomy, Prosthesis Failure, Voice

Keywords

voice prosthesis, laryngectomy, complications

Brief summary

The tracheoesophageal voice with voice prosthesis is currently the mainstay of voice rehabilitation post laryngectomy. The primary surgical technique of tracheoesophageal fistula formation with insertion of prosthesis and quick and easy process of voice rehabilitation are main encouraging factors. However, the usage of the prosthesis relates to a significant number of complications rated from 10 to 60%. The most common reported complication is transprosthetic leakage that determines the need of device exchange. However in some patients occur more serious complications eg. periprosthetic leakage, granulation or atrophy of mucosa around the fistula, dislocation of prosthesis, that may require anti-inflammatory treatment, temporary nasogastric tube feeding or surgical procedure. The standard protocol is voice prosthesis exchange due to transprosthetic leakage. Optionally the device could be replaced regularly to prevent both transprosthetic leakage and other complication occurrence. In the study we plan to compare the benefits from regular (each three month) versus leakage-related exchange of voice prosthesis post laryngectomy including the rate of complications, fistula colonization by Candida species and patients feedback.

Interventions

DEVICEProvox prosthesis exchange

Each patient post laryngectomy will be randomly assigned to one arm of intervention. The voice prosthesis exchange in all patients will be performed in local anaesthesia. The microbiological samples with cotton swabs will be collected from tracheoesophageal fistula on prosthesis exchange. The clinical evaluation and patients satisfaction from prosthesis usage will be performed on each exchange.

Sponsors

Medical University of Warsaw
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

randomized controlled trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients post laryngectomy with primary insertion of voice prosthesis

Exclusion criteria

* patients post laryngopharyngectomy with digestive tract reconstruction with jejunum of free flap

Design outcomes

Primary

MeasureTime frameDescription
Comparison of complications rate.Control will be continued for 12 months post laryngectomy.In both arms of the study we will compare the incidence of following complications: periprosthetic leakage, granulation or atrophy of mucosa around the fistula, dislocation of prosthesis

Secondary

MeasureTime frameDescription
Fistula colonization with Candida species.Control will be continued for 12 months post laryngectomy.We will compare microbiological results on subsequent prosthesis exchanges in both arms.
Prosthesis replacement scheme and patient satisfaction.Control will be continued for 12 months post laryngectomy.On each voice prosthesis exchange patients will be asked three questions, assessed with Visual Analog Scale, on their feedback on voice prosthesis use, procedure of prosthesis replacement and voice quality.

Countries

Poland

Contacts

Primary ContactAnna Rzepakowska, PhD
arzepakowska@wum.edu.pl+48225992521
Backup ContactDaniel Majszyk, PhD
daniel.majszyk@wum.edu.pl+48225992521

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026